Hypertension and Nutrigenetics

Yıl 2025, Cilt: 47 Sayı: 3, 504 - 513, 02.05.2025

İlsu Aldatmaz , Rumeysa Sultan Çevik , Ahmet Murat Günal

https://doi.org/10.20515/otd.1619821

Öz

Hypertension is a multifactorial disease characterized by systolic blood pressure values of 140 mmHg or more and/or diastolic blood pressure values exceeding 90 mmHg and is caused by a complex interaction of genetic and environmental factors. Dietary habits play a critical role among these environmental factors and can significantly affect the risk of hypertension in interaction with genetic predisposition. Recent nutrigenetic research has revealed in more detail the different responses of individuals' genetic makeup to nutrient intake and the effects of these responses on the development of hypertension. Genetic polymorphisms, especially single nucleotide polymorphisms, may affect risk levels by modulating the physiological responses of individuals to nutrients and thus hypertension. Therefore, personalized nutritional approaches tailored to individuals' genetic profiles are considered an effective strategy for the prevention and management of hypertension. This approach has the potential to make significant contributions to the development of more individualized and targeted treatment methods by taking into account the complex interaction between genetics and nutrition.

Anahtar Kelimeler

Hypertension , Nutrigenetics , Polymorphism

Hipertansiyon ve Nutrigenetik

Öz

Hipertansiyon, 140 mmHg veya daha yüksek sistolik ve/veya 90 mmHg'yi aşan diyastolik kan basıncı değerleriyle tanımlanan, genetik ve çevresel faktörlerin karmaşık etkileşimi sonucu ortaya çıkan multifaktöriyel bir hastalıktır. Beslenme alışkanlıkları, bu çevresel faktörler arasında kritik bir rol oynamakta ve genetik yatkınlıkla etkileşim halinde hipertansiyon riskini önemli ölçüde etkileyebilmektedir. Son yıllarda yapılan nutrigenetik araştırmalar, bireylerin genetik yapılarının besin alımına verdiği farklı yanıtları ve bu yanıtların hipertansiyon gelişimi üzerindeki etkilerini daha detaylı bir şekilde ortaya koymaktadır. Genetik polimorfizmler, özellikle tek nükleotid polimorfizmleri, bireylerin besinlere ve dolayısıyla hipertansiyona karşı gösterdikleri fizyolojik yanıtları modüle ederek risk düzeylerini etkileyebilmektedir. Bu nedenle, bireylerin genetik profillerine uygun kişiselleştirilmiş beslenme yaklaşımları, hipertansiyonun önlenmesi ve yönetimi için etkili bir strateji olarak değerlendirilmektedir. Bu yaklaşım, genetik ve beslenme arasındaki kompleks etkileşimi dikkate alarak, daha bireyselleştirilmiş ve hedefe yönelik tedavi yöntemlerinin geliştirilmesine önemli katkılar sağlayabilme potansiyeline sahiptir.

Anahtar Kelimeler

Hipertansiyon , Nutrigenetik , Polimorfizm

Kaynakça

• 1. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;1–107.
• 2. Povlsen AL, Grimm D, Wehland M, Infanger M, Krüger M. The Vasoactive Mas Receptor in Essential Hypertension. J Clin Med. 2020;9(1):267.
• 3. Wang L, Song TT, Dong CW. Association between Interactions among ACE Gene Polymorphisms and Essential Hypertension in Patients in the Hefei Region, Anhui, China. Journal of the Renin-Angiotensin-Aldosterone System, 2023, 1159973.
• 4. Xu J, Boström AE, Saeed M, Dubey RK, Waeber G, Vollenweider P, et al. A genetic variant in the catechol-O-methyl transferase (COMT) gene is related to age-dependent differences in the therapeutic effect of calcium-channel blockers. Med (United States). 2017;96(30).
• 5. Manosroi W, Williams GH. Genetics of Human Primary Hypertension: Focus on Hormonal Mechanisms. Endocr Rev. 2019;40(3):825–56. 6. Peña-Romero AC, Navas-Carrillo D, Marín F, Orenes-Piñero E. The future of nutrition: Nutrigenomics and nutrigenetics in obesity and cardiovascular diseases. Crit Rev Food Sci Nutr. 2018;58(17):3030–41.
• 7. Mahapatra NR, Ghosh S, Mahata M, Bandyopadhyay GK, Mahata SK. Naturally Occurring Single Nucleotide Polymorphisms in Human Chromogranin A (CHGA) Gene: Association with Hypertension and Associated Diseases. 2017;195–211.
• 8. Farhud D, Yeganeh MZ, Yeganeh MZ. Nutrigenomics and Nutrigenetics. Iran J Public Health. 2010;39(4):1.
• 9. Burrello J, Monticone S, Buffolo F, Tetti M, Veglio F, Williams TA, et al. Is There a Role for Genomics in the Management of Hypertension? Int J Mol Sci. 2017;18(6):1131.
• 10. Rodriguez-Iturbe B, Johnson RJ. Genetic Polymorphisms in Hypertension: Are We Missing the Immune Connection? Am J Hypertens. 2019;32(2):113–22.
• 11. Giovanella J, Wollinger LM, Capra L, Dresch F, Genro JP, Contini V. Diet-gene interaction: effects of polymorphisms in the ACE, AGT and BDKRB2 genes and the consumption of sodium, potassium, calcium, and magnesium on blood pressure of normotensive adult individuals. Mol Cell Biochem. 2021;476(2):1211–9.
• 12. Kılınç K, Bedir A, Nurol A. Esansi̇yel hi̇pertansi̇yonlu hastalarda m235t anji̇otensi̇nojen gen poli̇morfi̇zmi̇ angiotensinogen gene polymorphism in patients with essential hypertension. 2016;5(2):56–63.
• 13. Gatti RR, Santos PS, Sena AAS, Marangoni K, Araújo MA, Goulart LR. The interaction of AGT and NOS3 gene polymorphisms with conventional risk factors increases predisposition to hypertension. JRAAS - J Renin-Angiotensin-Aldosterone Syst. 2013;14(4):360–8.
• 14. Shivkar RR, Gawade GC, Padwal MK, Diwan AG, Mahajan SA, Kadam CY. Association of MTHFR C677T (rs1801133) and A1298C (rs1801131) Polymorphisms with Serum Homocysteine, Folate and Vitamin B12 in Patients with Young Coronary Artery Disease. Indian J Clin Biochem. 2022;37(2):224–31.
• 15. Zhong F, Zhuang L, Wang Y, Ma Y. Homocysteine levels and risk of essential hypertension: A meta-analysis of published epidemiological studies. Clin Exp Hypertens. 2017;39(2):160–7.
• 16. Wu Y Le, Hu CY, Lu SS, Gong FF, Feng F, Qian ZZ, et al. Association between methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and essential hypertension: A systematic review and meta-analysis. Metabolism. 2014;63(12):1503–11.
• 17. Albar MG. Esansiyel hipertansiyonlu hastalarda katekol o-metiltransferaz polimorfizmlerinin belirlenmesi. Yüksek Lisans Tezi. İstanbul: Marmara Universitesi Sağlık Bilimleri Enstitüsü, Biyofizik Anabilim Dalı, 2019.
• 18. Chi Htun N, Miyaki K, Song Y, Ikeda S, Shimbo T, Muramatsu M. Association of the Catechol-O-Methyl Transferase Gene Val158Met Polymorphism With Blood Pressure and Prevalence of Hypertension: Interaction With Dietary Energy Intake. Am J Hypertens. 2011;24(9):1022–6.
• 19. Mokhtari E, Hajhashemy Z, Saneei P. Serum Vitamin D Levels in Relation to Hypertension and Pre-hypertension in Adults: A Systematic Review and Dose–Response Meta-Analysis of Epidemiologic Studies. Front Nutr. 2022;9:829307.
• 20. Elbehairy MM, Abdelnasser HY, Hanafi RS, Hassanein SI, Gad MZ. An intronic DHCR7 genetic polymorphism associates with vitamin D serum level and incidence of acute coronary syndrome. Steroids. 2021;169:108825.
• 21. Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 2014;21(3):319–29.
• 22. Lafi ZM, Irshaid YM, El-Khateeb M, Ajlouni KM, Hyassat D. Association of rs7041 and rs4588 Polymorphisms of the Vitamin D Binding Protein and the rs10741657 Polymorphism of CYP2R1 with Vitamin D Status Among Jordanian Patients. 2015;19(11):629–36.
• 23. Sheikh V, Mozaianimonfared A, Gharakhani M, Poorolajal J, Ph.D. Effect of vitamin D supplementation versus placebo on essential hypertension in patients with vitamin D deficiency: a double-blind randomized clinical trial. J Clin Hypertens. 2020;22(10):1867–73.
• 24. Shi J, Liu Y, Liu Y, Li Y, Qiu S, Bai Y, et al. Association between ApoE polymorphism and hypertension: A meta-analysis of 28 studies including 5898 cases and 7518 controls. Gene. 2018;675:197–207.
• 25. Huebbe P, Rimbach G. Evolution of human apolipoprotein E (APOE) isoforms: Gene structure, protein function and interaction with dietary factors. Ageing Res Rev. 2017;37:146–61.
• 26. Eser M, Şanlıalp M, Tepeli E, Tufan LŞ, Kaftan A, Semerci CN, et al. Esansiyel hipertansiyonlu olgularda CHGA geni promotor bölge polimorfizmlerinin araştırılması. Pam Med J. 2015; 1: 23-30.
• 27. Alves-Lopes R, Neves KB, Touyz RM. Muscarinic Receptor Type-3 in Hypertension and Cholinergic-Adrenergic Crosstalk: Genetic Insights and Potential for New Antihypertensive Targets. Can J Cardiol. 2019;35(5):555–7.
• 28. Zhang X, Yao S, Bao P, Du M, Hu G, Chu C, et al. Associations of genetic variations in the M3 receptor with salt sensitivity, longitudinal changes in blood pressure and the incidence of hypertension in Chinese adults. J Clin Hypertens. 2024;26(1):36–46.
• 29. Zhang Y, Chang P, Liu Z. ADD1 Single Nucleotide Polymorphisms Are Associated With Essential Hypertension Among Han and Mongolian Population in Inner Mongolia Area. Front Genet. 2022;13:931803.
• 30. Zhang JR, Hu WN, Li CY. A Review of the Epidemiological Evidence for Adducin Family Gene Polymorphisms and Hypertension. Cardiol Res Pract. 2019;2019(1):7135604.
• 31. McDonough CW. Pharmacogenomics in Cardiovascular Diseases. Curr Protoc. 2021;1(7):e189.
• 32. Gildea JJ, Xu P, Carlson JM, Gaglione RT, Wang DB, Kemp BA, et al. The sodium-bicarbonate cotransporter NBCE2 (slc4a5) expressed in human renal proximal tubules shows increased apical expression under high-salt conditions. Am J Physiol - Regul Integr Comp Physiol. 2015;309(11):R1447–59.
• 33. Felder RA, Jose PA, Xu P, Gildea JJ. The Renal Sodium Bicarbonate Cotransporter NBCe2: Is It a Major Contributor to Sodium and pH Homeostasis? Curr Hypertens Rep. 2016;18(9):1–9.
• 34. Kurnaz Gömleksiz Ö, İlikay S, Buğra Z, Öztürk O, Yılmaz-Aydoğan H. Koroner Kalp Hastalarında Cav1 Rs3807990 Varyasyonunun Lipid Profilinde Diyabetik Koşullara Göre Farklı Etkileri. İstanbul Tıp Fakültesi Derg. 2020;83(1):23–9.
• 35. Voruganti VS. Nutritional Genomics of Cardiovascular Disease. Curr Genet Med Reports. 2018;6(2):98–106.
• 36. Alathari BE, Bodhini D, Jayashri R, Lakshmipriya N, Rani SS, Sudha V, et al. A Nutrigenetic Approach to Investigate the Relationship between Metabolic Traits and Vitamin D Status in an Asian Indian Population. Nutr. 2020;12(5):1357.
• 37. Barrea L, Annunziata G, Bordoni L, Muscogiuri G, Colao A, Savastano S. Nutrigenetics—personalized nutrition in obesity and cardiovascular diseases. Int J Obes Suppl. 2020;10(1):1–13.
• 38. Du B, Tian H, Tian D, Zhang C, Wang W, Wang L, et al. Genetic polymorphisms of key enzymes in folate metabolism affect the efficacy of folate therapy in patients with hyperhomocysteinaemia. Br J Nutr. 2018;119(8):887–95.
• 39. Husemoen LLN, Skaaby T, Thuesen BH, Grarup N, Sandholt CH, Hansen T, et al. Mendelian randomisation study of the associations of vitamin B12 and folate genetic risk scores with blood pressure and fasting serum lipid levels in three Danish population-based studies. Eur J Clin Nutr.;70(5):613–9.
• 40. Bercea CI, Cottrell GS, Tamagnini F, McNeish AJ. Omega-3 polyunsaturated fatty acids and hypertension: a review of vasodilatory mechanisms of docosahexaenoic acid and eicosapentaenoic acid. Br J Pharmacol. 2021;178(4):860–77.
• 41. Ferguson JF, Phillips CM, McMonagle J, Pérez-Martínez P, Shaw DI, Lovegrove JA, et al. NOS3 gene polymorphisms are associated with risk markers of cardiovascular disease, and interact with omega-3 polyunsaturated fatty acids. Atherosclerosis. 2010;211(2):539–44.
• 42. Marcotte BV, Guénard F, Lemieux S, Couture P, Rudkowska I, Calder PC, et al. Fine mapping of genome-wide association study signals to identify genetic markers of the plasma triglyceride response to an omega-3 fatty acid supplementation. Am J Clin Nutr. 2019;109(1):176–85.
• 43. Dong OM. Excessive dietary sodium intake and elevated blood pressure: a review of current prevention and management strategies and the emerging role of pharmaconutrigenetics. BMJ Nutr Prev Heal. 2018;1(1):7.
• 44. Onwuzo C, Olukorode J o, Omokore OA, Odunaike OS, Omiko R, Osaghae O w, et al. DASH Diet: A Review of Its Scientifically Proven Hypertension Reduction and Health Benefits. Cureus. 2023;15(9):e44692.
• 45. Singh V. Current challenges and future implications of exploiting the omics data into nutrigenetics and nutrigenomics for personalized diagnosis and nutrition-based care. Nutrition. 2023;110:112002.
• 46. Ceriani F, Montalvan M, Quintero B, Suárez R, Bautista-Valarezo E, Frias-Toral E. Ethics of the clinical practice of nutrigenetics and nutrigenomics. Clin Nutr Open Sci. 2023;49:58–66.
• 47. Borges MC, Hartwig FP, Oliveira IO, Horta BL. Is there a causal role for homocysteine concentration in blood pressure? A Mendelian randomization study. Am J Clin Nutr. 2016;103(1):39–49.
• 48. Jiang L, Sun YQ, Denos M, Brumpton BM, Chen Y, Malmo V, Et Al. Investigating the relationship of serum vitamin D levels with blood pressure and hypertension risk in the HUNT study: using traditional observational and mendelian randomization approaches. Medrxiv. 2024.
• 49. Dumont J, Huybrechts I, Spinneker A, Gottrand F, Grammatikaki E, Bevilacqua N, et al. FADS1 genetic variability interacts with dietary α-linolenic acid intake to affect serum non-HDL-cholesterol concentrations in European adolescents. J Nutr. 2011;141(7):1247–53.